“After treatment with enzalutamide, PSA levels decline due to potent androgen receptor blockade and cell death,” Armstrong ...

Tirzepatide (Mounjaro; Eli Lilly), a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide ...

Dupilumab shows significant benefits in prurigo nodularis severity and healing outcomes. Learn more about the latest Phase III trial findings.

Central sleep apnea (CSA) is fundamentally different from obstructive sleep apnea (OSA). The former is characterized by ...

CAMBRIDGE, MA / ACCESS Newswire / April 6, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that the Company will ...

Opus Genetics and Viatris (through its affiliate) are parties to a global licensing agreement which provides for the development of phentolamine ophthalmic solution 0.75% and grants exclusive rights ...

The data are limited but suggest the tricuspid valve procedure can do more than improve health status, researchers say.

MediWound to Present New EscharEx® Data at Leading Wound Care Conferences Data highlights mechanism of action, outcomes in VLUs and DFUs, and ...

RESEARCH TRIANGLE PARK, N.C., April 10, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore visi ...

The geographic atrophy (GA) enlargement rate in one eye does not consistently predict the enlargement rate in the fellow eye, ...

Trials of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, are documenting its direct kidney effects and broad benefits for diabetic kidney disease.

Use of tirzepatide, compared with dulaglutide, is associated with a 20% lower risk for MACE among patients with T2D and ASCVD.